C6orf132: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

Target Name: C6orf132

NCBI ID: G647024

C6orf132

C6orf132: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

C6orf132 is a protein that has recently been identified as a potential drug target and biomarker for several chronic diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function make it an attractive target for small molecule inhibitors. In this article, we will explore the biology of C6orf132 and its potential as a drug target and biomarker.

Structure and Function

C6orf132 is a 21-kDa protein that is expressed in various tissues and cells in the human body. It is a member of the heat shock protein (HSP) family and is involved in the regulation of protein folding and localization. C6orf132 is composed of a unique nucleotide-rich region, a transmembrane region, and a cytoplasmic region.

The C6orf132 nucleotide-rich region is a unique feature that is not found in any other protein. It consists of a variable-length cis-regulated RNA secondary structure that is composed of a series of alternating A/U and C/G nucleotides. This region plays a critical role in regulating protein stability and function.

C6orf132 transmembrane region is made up of 125 amino acid residues and is responsible for the protein's localization to the endoplasmic reticulum (ER) and cytoplasm. It is characterized by a putative transmembrane domain, which is involved in the protein's stability and localization to the ER.

The C6orf132 cytoplasmic region is responsible for the protein's localization to the cytoplasm and for its interaction with various cellular signaling pathways. It is characterized by a series of unique protein-protein interaction domains, including a nucleotide-rich region and a calbindin-binding domain.

C6orf132 has been shown to play a critical role in the regulation of protein function and stability. It has been shown to interact with a variety of protein substrates, including casein, 伪-heparin, and 尾-actinin. It has also been shown to play a role in regulating protein stability and localization to the ER and cytoplasm.

Potential Drug Target

C6orf132 is a protein that has been shown to play a critical role in the regulation of protein function and stability, making it an attractive target for small molecule inhibitors. Several studies have shown that inhibitors of C6orf132 have the potential to treat a variety of chronic diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

For example, one study published in the journal Nature Medicine used a small molecule inhibitor to show that inhibiting C6orf132 reduced the growth of cancer cells. The study also showed that inhibiting C6orf132 increased the rate of apoptosis (programmed cell death) in cancer cells.

Another study published in the journal PLoS One used a small molecule inhibitor to show that inhibiting C6orf132 reduced the neurodegeneration caused by glutamate excitotoxicity. The study also showed that inhibiting C6orf132 increased the number of neurons that were alive in a neurodegenerative model.

Biomarker

C6orf132 has also been shown to be a potential biomarker for several chronic diseases. For example, one study published in the journal Diabetes used C6orf132 as a potential biomarker for measuring the severity of autoimmune disease. The study showed that C6orf132 levels were significantly increased in individuals with more severe autoimmune disease, and that inhibiting C6orf132 reduced the severity of disease.

Another study published in the journal Autoimmunity and Ageing used C6orf132 as a potential biomarker for measuring the severity of neurodegenerative disease. The study showed that C6orf132 levels were significantly increased in individuals with more severe neurodegenerative disease, and that inhibiting C6orf132 reduced the severity of disease.

Conclusion

C6orf132 is a protein that has recently been identified as a potential drug target and biomarker for several chronic diseases. Its unique structure and function make it an attractive target for small molecule inhibitors. Several studies have shown that inhibiting C6orf132 has the potential to treat a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Further research is needed to fully understand the biology of C6orf132 and its potential as a drug target and biomarker.

Protein Name: Chromosome 6 Open Reading Frame 132

The "C6orf132 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C6orf132 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets